Danaparoid sodium

Bibliography

• HIRSH J: Heparin. N. Engl. J. Med. (1991) 324(22):1565–1574.
   PubMed Web of Science ®Google Scholar
• •A thorough review on heparin.
   Google Scholar
• WEITZ JI: Low-molecular-weight heparins. N. Engl. J. Med. (1997) 337(10):688–698.
   PubMed Web of Science ®Google Scholar
• •A review of LMWH.
   Google Scholar
• DOLOVICH LRP, JEFFREY S, FRCPC, CHEAH GB: A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type and dosing frequency. Arch. Intern. Med. (2000) 160(2):181–188.
   PubMedGoogle Scholar
• WARKENTIN TE, LEVINE MN, HIRSH J et al.: Heparin- induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. .1. Med. (1995) 332(20):1330–1335.
   Google Scholar
• •A double-blind clinical trial of the incidence HIT/HITT in patients treated with UFH vs. LMWH
   Google Scholar
• SUH JS, ASTER RH, VISENTIN GP: Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis recognize different epitopes on heparin: platelet factor 4. Blood (1998) 91(3):916–922.
   PubMed Web of Science ®Google Scholar
• •A detailed article on antiheparin antibodies.
   Google Scholar
• SCHIELE F, VUILLEMONT A, KRAMARZ P et al.: Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am. J. Hematol. (1995) 50(020–25.
   PubMed Web of Science ®Google Scholar
• GREINACHER A, VOLPEL H, JANSSENS U et al.: Recombi-nant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation (1999) 99(1):73–80.
   PubMed Web of Science ®Google Scholar
• •A prospective study of the use of hirudin in HIT (HAT-1).
   Google Scholar
• GREINACHER A, JANSSENS U, BERG G et al.: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation (1999) 100(6):587–593.
   Google Scholar
• •A prospective study of the use of hirudin in HIT (HAT-2).
   Google Scholar
• BUCHA E, KREML R, NOWAK G: In vitro study of r-hirudin permeability through membranes of different haemodialysers. Neph. Dial. Transp. (1999) 14(12):2922–2926.
   PubMed Web of Science ®Google Scholar
• AVENTIS: Refludan'aPackage Insert.
   Google Scholar
• ERIKSSON BI, WILLE-JORGENSEN P, KALEBO P et al.: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med. (1997) 337(19):1329–1335.
   PubMed Web of Science ®Google Scholar
• HUHLE G, HOFFMANN U, SONG X, WANG LC, HEENE DL,HARENBERG J: Immunologic response to recombinant hirudin in HIT Type II patients during long-term treatment. Br. J. Haematol. (1999) 106(0195–201.
   PubMed Web of Science ®Google Scholar
• MATSUO T, KARIO K, CHIKAHIRA Y, NAKAO K, YAMADA T: Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br. J. Haematol. (1992) 82(3):627–629.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, IAFFALDANO R, MCKIERNAN TL, RAO L, DONKIN J, WALLENGA JM: Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Cath. Cardiovasc. Diag. (1996) 38(4:206–209.
   PubMedGoogle Scholar
• HURSTING MJ, ALFORD KL, BECKER JC et al.: Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin. Thromb. Haemost. (1997) 23(6):503–516.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, FASANELLA AR, IQBAL 0 et al.: Coagula-tion laboratory testing in patients treated with argatroban. Semin. Thromb. Hemost. (1999) 25\(Suppl. 0:61–66.
   Google Scholar
• LEWIS BE, WALLIS DE, MATTHAI W: Argatroban provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia: a prospec-tive, historical controlled study. JACC (2000) 35\(Suppl. 1):266A.
   Google Scholar
• POLLAK VE, GLAS-GREENWALT P, OLINGER CP, WADHWA NK, MYRE SA: Ancrod causes rapid thrombolysis in patients with acute stroke. Am.J. Med. Sci. (1990) 299(9:319–325.
   PubMedGoogle Scholar
• DEMERS C, GINSBERG JS, BRILL-EDWARDS P et al Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood (1991) 78(9):2194–2197.
   PubMed Web of Science ®Google Scholar
• WARKENTIN TE: Limitations of conventional treatmentoptions for heparin-induced thrombocytopenia. Semin. Hematol. (1998) 35(4, Suppl. 5):17–25.
   Google Scholar
• ERIKSSON H, ERIKSSON UG, FRISON L et al.: Pharma-cokinetics and pharmacodynarnics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost (1999) 81(3):358–363.
   PubMed Web of Science ®Google Scholar
• MEULEMAN DG: Orgaran (Org 10172): its pharmacol-ogical proffle in experimental models. Haemostasis (1992) 22(2):58–65.
   PubMedGoogle Scholar
• MEULEMAN DG, HOBBELEN PM, VAN DEDEM G et al.: Anovel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharma-cological properties in experimental animal models. Thromb Res (1982) 27(3):353–363.
   Google Scholar
• AVENTIS: LovenoxTmPackage Insert.
   Google Scholar
• MIKHAILIDIS DP, FONSECA VA, BARRADAS MA, JEREMYJY, DANDONA P: Platelet activation following intrave-nous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br. J. Clin. Pharmacol. (1987) 24(4):415–424.
   PubMed Web of Science ®Google Scholar
• BAGLIN TP: Heparin-induced thrombocy-topenia/thrombosis syndrome (HIT): diagnosis and treatment. Proceedings of a workshop held in London on 1 November 1996. Platelets (1997) 8:65–67.
   Google Scholar
• KEELING DM, RICHARDS EM, BAGLIN TP: Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia. Br. J. Haematol. (1994) 86(2):425–426.
   PubMed Web of Science ®Google Scholar
• •A study of the effects of LMWH and danaparoid on platelet aggregation.
   Google Scholar
• MAGNANI HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb. Haemost. (1993) 70(4):554–561.
   PubMed Web of Science ®Google Scholar
• •A detailed overview of 230 patients with HIT treated with danaparoid.
   Google Scholar
• HOBBELEN PM, VAN DINTHER TG, VOGEL GM, VAN BOECKEL CA, MOELKER HC, MEULEMAN DG: Pharma-cological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb. Haemost. (1990) 63(2):265–270.
   PubMed Web of Science ®Google Scholar
• DANHOF M, DE BOER A, MAGNANI HN, STIEKEMA JC:Pharrnacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis. (1992) 22(2):73–84.
   PubMedGoogle Scholar
• BRADBROOK ID, MAGNANI HN, MOELKER HC eta/.: ORG10172: a low molecular weight heparinoid anticoagu-lant with a long half-life in man. Br. J Clin. Pharmacol. (1987) 23(6):667–675.
   Google Scholar
• •An early description of the use of danaparoid in normal healthy volunteers.
   Google Scholar
• DE BOER A, STIEKEMA JC, DANHOF M, BREIMER DD: The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172. Br. J. Clin. Pharmacol. (1991) 32(1):23–29.
   PubMed Web of Science ®Google Scholar
• ORGANON: OrgaranT' Package Insert.
   Google Scholar
• WILDE MI, MARKHAM A: Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs (1997) 54(6):903–924.
   Google Scholar
• TEN GATE JW: Prevention of deep vein thrombosis following total hip replacement surgery by Orgaran. Summary. Haemostasis (1992) 22(2):109–111.
   PubMedGoogle Scholar
• HOEK JA, NURMOHAMED MT, HAMELYNCK KJ et al.: Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb. Haemost. (1992) 67(1):28–32.
   PubMed Web of Science ®Google Scholar
• •A randomised double-blind placebo-controlled trial of danaparoid in elective total hip replacement.
   Google Scholar
• BERGQVIST D, KETTUNEN K, FREDIN H et al.: Thrombo-prophylaxis in patients with hip fractures: a prospec-tive, randomized, comparative study between Org 10172 and dextran 70. Surgery (1991) 109(5):617–622.
   PubMed Web of Science ®Google Scholar
• GENT M, HIRSH J, GINSBERG JS et al.: Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembo-lism after surgery for hip fracture. Circulation (1996) 93(1):80–84.
   PubMed Web of Science ®Google Scholar
• Orgaran Research Protocol 004–023.
   Google Scholar
• SKOUTAKIS VA: Danaparoid in the prevention of thromboembolic complications. Ann. Pharmacother. (1997) 31(7-8):876–887.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of danaparoid.
   Google Scholar
• DE VALK HW, BANGA JD, WESTER JW et al.: Comparing subcutaneous danaparoid with intravenous unfrac-tionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann. Intern. Med. (1995) 123(1):1–9.
   PubMed Web of Science ®Google Scholar
• CHONG BH, MAGNANI HN: Orgaran in heparin-induced thrombocytopenia. Haemostasis (1992) 22(2):85–91.
   PubMedGoogle Scholar
• MAGNANI HN: Orgaran (danaparoid sodium) use in thesyndrome of heparin-induced thrombocytopenia. Proceedings of a workshop held in London on 1 November 1996. Platelets (1997) 8:74–81.
   Google Scholar
• WARKENTIN TE: Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (hit) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation and evaluation of the clinical significance of in vitro Cross-reactivity (XR) of Danaparoid for HIT-IgG. Blood (1996) 88(Suppl.):626a.
   Google Scholar
• HIRSH J, WARKENTIN TE, RASCHKE R, GRANGER C, OHMAN EM, DALEN JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacoki-netics, dosing considerations, monitoring, efficacy and safety. Chest (1998) 114\(Suppl. 5):4895-510S.
   Google Scholar
• VUN CM, EVANS S, CHONG BH: Cross-reactivity study oflow molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb. Res. (1996) 81(9:525–532.
   PubMedGoogle Scholar
• ORTEL TL, GOCKERMAN JP, CALIFF RM et al.: Parenteralanticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocy-topenia and thrombosis. Thromb Haemost (1992) 67(3)292–296.
   Google Scholar
• TARDY-PONCET B, TARDY B, REYNAUD J et al Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest (1999) 115(6):1616–1620.
   PubMed Web of Science ®Google Scholar
• GALLUS A, CADE J, OCKELFORD P et al.: Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group. Thromb. Haemost. (1993) 70(4):562–567.
   PubMed Web of Science ®Google Scholar
• •A double-blind randomised multi-centre trial of VTE prophylaxis with heparin versus danaparoid in 513 patients having elective surgery
   Google Scholar
• COMP PC, VOEGELI T, MCCUTCHEN JW, SKOUTAKIS VA,TROWBRIDGE A, OVERDYKE WL: A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: the Danaparoid Hip Arthroplasty Investigators Group. Orthopedics (1998) 21(10)1123–1128.
   Google Scholar
• WADE WE: Cost effectiveness of danaparoid comparedwith enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery. Am. J. Orthoped. (1999) 28(4):229–231.
   PubMedGoogle Scholar
• MAGNANI HN, BEIJERING RJR TEN CATE JW, CHONG BH: Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: New Anticoagulants for the Cardiovascular Patient. Pifarre R (Ed.), Hanley & Belfus, Inc. (1997):487–500.
   Google Scholar
• •A thorough review of the use of danaparoid in cardiopul-monary bypass.
   Google Scholar
• HALE LP, SMITH K, BRADEN GA, OWEN J: Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Cathet. Cardio-vasc. Diag. (1998) 45(9:318–322.
   PubMedGoogle Scholar
• •A case report of the successful use of danaparoid in PTCRA.
   Google Scholar